Iressa (gefitinib, ZD1839) - anti-cancer drug treats non-small-cell lung cancer (NSCLC)

Go to navigation
Go to content

IRESSA (gefitinib) is an epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor, that acts to block signals for cancer cell growth and survival in non-small cell lung cancer.

Did you know?

AstraZeneca has a range of product specific and disease area websites for international healthcare professionals and patients. Links to this information can be found below.

Links to country-specific websites can be found using the AstraZeneca websites list.

If you still have a question regarding our drug portfolio you can Contact us.

Not signed in

Page tools

Share price

London: 32.38 GBP
New York: 50.44 USD
Stockholm: 368.30 SEK

At 01-Aug-2010 06:45 GMT

Detailed share price

Helping to dispel the myths

Alongside our ongoing research, we are working at a local level to set the record straight on some key lung cancer issues

Contact us

Contact us

Email enquiry form

Read more

Path to a new medicine

Recent collaborations

Access to medicines

This website is intended for people seeking information on the AstraZeneca International business. If you are in the US you should visit AstraZeneca US.

We also have national business sites which can be found under our list of AstraZeneca websites.

We also have specific national and international websites designed for patients and healthcare professionals. If you have a question you can contact us.